Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Alex C Spyropoulos, Jerrold H Levy, Walter Ageno, Jean Marie Connors, Beverley J Hunt, Toshiaki Iba, Marcel Levi, Charles Marc Samama, Jecko Thachil, Dimitrios Giannis, James D Douketis, Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis, Alex C Spyropoulos, Jerrold H Levy, Walter Ageno, Jean Marie Connors, Beverley J Hunt, Toshiaki Iba, Marcel Levi, Charles Marc Samama, Jecko Thachil, Dimitrios Giannis, James D Douketis, Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis

No abstract available

Keywords: SARS-CoV-2; anticoagulant; antithrombotic therapy; coronavirus disease 2019; hospitalization.

References

    1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Novel Coronavirus (2019‐nCoV) situation reports n.d. . (Accessed March 17, 2020).
    1. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19. Thromb Res. 2020;191:145–147.
    1. Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424.
    1. Obi A.T., Tignanelli C.J., Jacobs B.N., et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019;7:317–324.
    1. Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID‐19, SARS‐CoV‐1, MERS‐CoV and lessons from the past. J Clin Virol. 2020;127
    1. Driggin E., Madhavan M.V., Bikdeli B., et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID‐19) pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371.
    1. Spyropoulos A.C., Raskob G.E. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017;117:1662–1670.
    1. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023–1026.
    1. Bikdeli B., Lobo J.L., Jiménez D., et al. Early use of echocardiography in patients with acute pulmonary embolism: findings from the RIETE registry. J Am Heart Assoc. 2018;7
    1. Kahn S.R., Lim W., Dunn A.S., et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence‐based clinical practice guidelines. Chest. 2012;141:e195S–e226S.
    1. Schünemann H.J., Cushman M., Burnett A.E., et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2:3198–3225.
    1. Barbar S., Noventa F., Rossetto V., et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450–2457.
    1. Spyropoulos A.C., Anderson F.A., FitzGerald G., et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140:706–714.
    1. Greene M.T., Spyropoulos A.C., Chopra V., et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med. 2016;129:1001.e9–1001.e18.
    1. Mahan C.E., Liu Y., Turpie A.G., et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely‐ill medical patient (VTE‐VALOURR) Thromb Haemost. 2014;112:692–699.
    1. Rosenberg D., Eichorn A., Alarcon M., McCullagh L., McGinn T., Spyropoulos A.C. External validation of the risk assessment model of the international medical prevention registry on venous thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3(6)
    1. Wang T., Chen R., Liu C., et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID‐19. Lancet Haematol. 2020;7(5):e362–e363.
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.
    1. Ho K.M., Tan J.A. Stratified meta‐analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128:1003–1020.
    1. Fu L., Wang B., Yuan T., et al. Clinical characteristics of coronavirus disease 2019 (COVID‐19) in China: a systematic review and meta‐analysis. J Infect. 2020;80(6):656–665.
    1. Guo T., Fan Y., Chen M., et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID‐19) JAMA Cardiol. 2020;5(7):1–8.
    1. Mehta P., McAuley D.F., Brown M., et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034.
    1. Fox S, Akmatbekov A, Harbert J, Li G, Brown J, Vander Heide RPulmonary and cardiac pathology in Covid‐19: the first autopsy series from New Orleans. 2020;8(7):681‐686.
    1. Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID‐19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858.
    1. Wang J., Hajizadeh N., Moore E.E., et al. Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752–1755.
    1. OBE BH, Retter A, McClintock C.Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID‐19 n.d. (accessed April 10, 2020).
    1. Cohoon K.P., Mahé G., Tafur A.J., Spyropoulos A.C. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost. 2020;4(4):510–517.
    1. MacDougall K., Spyropoulos A.C. New paradigms of extended thromboprophylaxis in medically ill patients. J Clin Med. 2020;9(4):1002.
    1. Cohen A.T., Spiro T.E., Büller H.R., et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–523.
    1. Spyropoulos A.C., Lipardi C., Xu J., et al. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb. 2019;25
    1. Hull R.D., Schellong S.M., Tapson V.F., et al. Extended‐duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8–18.
    1. Cohoon K.P., Sanctis Y.D., Haskell L., McBane R.D., Spiro T.E. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018;16:1278–1287.
    1. Spyropoulos A.C., Lipardi C., Xu J., et al. Modified IMPROVE VTE risk score and elevated d‐dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open Companion J Thromb Haemost. 2020;4:e59–e65.
    1. Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa